ATLyphe is a Swiss biotech startup with the goal of developing antibody-based solutions engaging T cells for precision immunotherapy. We aim to not only provide less toxic and more precise treatments for current patients but also increase the total number of patients eligible to receive the therapy.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business